Core Insights - The report analyzes three representative AI asset management products: AIEQ, ProPicks, and QRFT, assessing whether AI can deliver excess returns for investors [2] - Overall, while overseas AI asset management products have improved quality and efficiency, they should not be overly "mythologized" [2] - AI's more reliable value lies in enhancing information processing efficiency and standardizing investment research processes rather than consistently outperforming indices [2] Group 1: AI-Driven Asset Management: Progress and Cases - The evolution of global financial markets reflects a historical contest between computational power and data processing capabilities [3] - Traditional quantitative investment relies on linear regression and statistical arbitrage, while AI-driven asset management represents a fundamental paradigm shift [3][4] - New AI stock selection strategies utilize deep learning, reinforcement learning, and natural language processing, enabling the identification of non-linear market patterns [4] Group 2: Case Study 1: AIEQ ETF Introduction - AIEQ is the world's first actively managed ETF entirely driven by AI, launched on October 17, 2017 [5] - The fund's investment strategy involves high-frequency scanning and sentiment analysis of the entire market information environment [5] - AIEQ's model processes millions of unstructured texts daily, aiming to capture undervalued stocks before market sentiment changes [5] Group 3: AIEQ Performance Analysis - As of November 2025, AIEQ's performance shows it has underperformed the S&P 500 index, with a YTD return of approximately 9.38% compared to the S&P 500's 12.45% [10] - Over one year, AIEQ returned about +6.15%, while the S&P 500 returned +11.00% [13] - AIEQ's high turnover rate of 1159% significantly impacts its performance, leading to cost erosion [18] Group 4: Case Study 2: Investing ProPicks - ProPicks represents a different AI investment approach through a subscription model, providing users with monthly stock selection lists [21] - The strategy leverages a vast historical database and AI algorithms to evaluate stocks based on over 50 financial indicators [21] - The "Tech Titans" strategy under ProPicks has achieved a cumulative return of 98.7%, significantly outperforming the S&P 500 by 55% [25] Group 5: Case Study 3: QRFT - QRFT employs AI to optimize a traditional factor investment framework, focusing on quality, size, value, momentum, and low volatility [39] - The fund's performance has been slightly better than the S&P 500, with a year-to-date return of approximately +21% as of November 2025 [44] - QRFT's high turnover rate of 267% indicates a high-frequency rebalancing strategy, which poses challenges in terms of cost and performance [48]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The pharmaceutical sector has underperformed the overall market, with a significant decline in various sub-sectors, including a 6.88% drop in the biotechnology sector [1][32] - Hidradenitis Suppurativa (HS) is identified as a chronic, recurrent inflammatory skin disease with a low prevalence in China and the U.S., highlighting the potential market for treatment options [2][10] - The report emphasizes the increasing market share of new biologics targeting IL-17A and IL-17A/F, which are expected to outperform traditional therapies like Adalimumab [17][18][22] Summary by Sections Market Performance - The overall A-share market declined by 4.32%, with the biotechnology sector falling by 6.88%, indicating a weaker performance compared to the broader market [1][32] - Specific declines were noted in chemical pharmaceuticals (7.02%), biological products (7.46%), and medical services (6.90%) [1][32] Hidradenitis Suppurativa (HS) Overview - HS affects approximately 0.03% of the population in China, with around 400,000 cases, and has been included in the rare disease directory [2][10] - The disease's complex pathogenesis involves multiple immune pathways, making it a target for various therapeutic approaches [11][27] Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already priced in risks from policy changes [42][43] - It highlights the potential for growth in the CXO sector, particularly in CDMO and clinical CRO segments, as they continue to show strong performance despite market challenges [42][43] Recommended Stocks - The report lists several companies with strong growth potential, including Mindray Medical, WuXi AppTec, and Aier Eye Hospital, all rated as "Outperform" [4][44] - Mindray Medical is noted for its robust R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [44]

Core Insights - The report highlights the emergence of TradingAgents-CN as a significant tool in the investment research landscape, integrating AI agents with local market data and strategy research tools to create a lightweight platform for individual investors and small to medium-sized investment institutions [2][3] - TradingAgents-CN aims to streamline the investment research process by unifying model, data, task flow, and decision explanation into a simplified framework, thus reducing the need for researchers to switch between multiple tools [3][4] - The platform allows users to deploy various types of agents for stock analysis, simulated trading, and sentiment monitoring, enhancing the decision-making process through real-time data communication and large-scale task scheduling [2][4] Functionality and Advantages - TradingAgents-CN positions AI as a research assistant rather than a black-box predictor, focusing on enhancing decision-making rather than replacing it, which aligns with current market expectations of AI [4][5] - The platform automates and structures the strategy research process, allowing for the organization of various data points into a timeline and structured JSON format for easier review and auditing [4][5] - It provides an open yet lightweight experimental environment, enabling researchers to quickly deploy and test multiple agents for collaborative tasks, significantly reducing the cost of experimentation compared to traditional systems [4][5] Impact on Investment Research - TradingAgents-CN transforms the traditional investment research workflow by automating complex processes, allowing users to generate comprehensive stock analysis reports with minimal input [6][7] - The system integrates various analytical components, including technical indicators and sentiment analysis, to produce structured investment recommendations, making professional-level analysis accessible to non-experts [7][8] - The platform represents a systematic application of AIGC technology in stock analysis, democratizing access to institutional-level research capabilities for ordinary investors and junior professionals [9] Integration of Research and Trading - TradingAgents-CN enhances the integration of research and trading by allowing users to execute simulated trades directly from the analysis results, thereby reducing friction in the trading process [11][12] - The system automatically populates trading parameters based on analysis outcomes, facilitating quick decision-making while maintaining a clear overview of account performance and historical transactions [12]

证券研究报告 | 2025年11月27日 AI 赋能资产配置（二十六） AI"添翼" ：大模型增强投资组合回报 ①本报告围绕三类代表性 AI 资管产品开展复盘对照：AIEQ、ProPicks、QRFT，回答 AI 能否为投资者带来 超额收益。②从结果看，当前海外 AI 资管产品总体提质增效但不宜过度"神化"：以情绪流为代表的主 动型 ETF AIEQ 长期跑输 SPY，关键在于受到市场情绪波动较大，且费率与极高换手带来成本侵蚀；订阅 性产品 ProPicks 在科技顺风期收益突出，但对执行纪律与滑点高度敏感，实际复现难度较高；AI 增强行 ETF QRFT 长期与标普接近，阶段性强弱分化明显，更偏窄幅增强而非稳定高 Alpha。③结论上，AI 更可靠 的价值在提升信息处理效率与投研流程标准化，而非保证持续战胜指数；判断产品靠不靠谱应优先看三点， 长期相对基准是否有净超额，费率与换手后的收益是否仍成立，信号与业绩披露是否可复盘、可验证。 一、AI 驱动型资产管理：进展与案例 全球金融市场的演进史，在某种程度上是一部计算能力与数据处理能力不断博弈的历史。从早期的格雷厄 姆式基本面分析，到 20 世纪 80 年代兴 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [7] Core Views - The company has raised its full-year revenue growth guidance to 35%, driven by strong retail business performance, with Q3 revenue growth of 38.4% year-on-year [1][10] - The hotel business continues to expand, with a net increase of 124 hotels in Q3 and a total of 1948 operating hotels, reflecting a 27% year-on-year growth [2][14] - The retail business has shown exceptional growth, with Q3 revenue increasing by 76.4%, leading to an upward revision of the full-year revenue growth target from 60% to 65% [3][15] - The company is positioned as a lifestyle brand targeting mid-to-high-end consumers, benefiting from the recovery of business activities in high-tier cities [4][16] Summary by Sections Financial Performance - In Q3 2025, the company reported revenue of 2.63 billion yuan, a year-on-year increase of 38.4%, and adjusted net profit of 490 million yuan, up 27% [1][10] - The company expects to achieve revenues of 9.82 billion, 12.29 billion, and 14.78 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 35.4%, 25.2%, and 20.2% [5][18] Hotel Business - The company opened 152 new hotels in Q3, bringing the total to 1948, with a target of 500 new openings for the year [2][14] - The RevPAR (Revenue per Available Room) for Q3 was 371 yuan, showing a slight decline of 2.2% year-on-year, but an improvement compared to previous quarters [3][15] Retail Business - The retail segment achieved a GMV of 999.4 million yuan in Q3, with revenue growth of 76.4%, contributing 32% to total revenue [3][15] - The introduction of the "Atour Planet Deep Sleep Standard" aims to enhance product offerings and strengthen brand positioning in the sleep industry [4][16]

证券研究报告 | 2025年11月27日 金融工程日报 沪指冲高回落，CPO 概念再度爆发、大消费尾盘发力 市场表现：20251126 规模指数中沪深 300 指数表现较好，板块指数中创业 板指表现较好，风格指数中沪深 300 成长指数表现较好。通信、电子、商贸 零售、家电、医药行业表现较好，国防军工、传媒、石油石化、银行、综合 金融行业表现较差。光模块(CPO)、光通信、光芯片、SPD、培育钻石等概念 表现较好，中船系、水产、航母、核废水、十大军工集团等概念表现较差。 机构关注与龙虎榜：近一周内调研机构较多的股票是立讯精密、九号公司 -WD、纳科诺尔、麦澜德、泰恩康、威胜信息、博盈特焊、三元生物等，立 讯精密被 396 家机构调研。20251126 披露龙虎榜数据中，机构专用席位净流 入前十的股票是长光华芯、中集集团、中环海陆、宁波色母、康芝药业、必 贝特-U、三木集团、特一药业、华人健康、清水源等，机构专用席位净流出 前十的股票是航天发展、上海港湾、榕基软件、华映科技、顺灏股份、品高 股份、欢瑞世纪、大洋电机、凯淳股份、佳缘科技等。陆股通净流入前十的 股票是东芯股份、永鼎股份、中船防务、航天动力、长光华芯 ...

证券研究报告 | 2025年11月26日 2025年11月27日 医药生物周报（25 年第 46 周） 优于大市 化脓性汗腺炎治疗药物梳理 本周医药板块表现弱于整体市场，医药商业板块领跌。本周全部 A 股下跌 4.32%（总市值加权平均），沪深 300 下跌 3.77%，中小板指下跌 5.10%， 创业板指下跌 6.15%，生物医药板块整体下跌 6.88%，生物医药板块表 现弱于整体市场。分子板块来看，化学制药下跌 7.02%，生物制品下跌 7.46%，医疗服务下跌 6.90%，医疗器械下跌 6.38%，医药商业下跌 7.67%，中药下跌 6.46%。医药生物市盈率（TTM）36.69x，处于近 5 年历史估值的 78.22%分位数。 化脓性汗腺炎治疗药物梳理。化脓性汗腺炎（HS）是一种慢性、复发性、 毁容性、炎症性皮肤病。一般认为西方人群的真实患病率~1%，美国确诊 HS 患者~32 万人（其中~20 万为中重度患者）；中国 HS 患病率~0.03%（~40 万人，已被列入第二批罕见病目录），其中中重度患者~30 万人。HS 一线 疗法以抗菌为主，二线生物制剂疗法主要为阿达木单抗（TNFα）、司库奇 尤单抗 ...

证券研究报告 | 2025年11月26日 2025年11月27日 股指分红点位监控周报 市场情绪转暖，各主力合约均贴水 核心观点 金融工程周报 成分股分红进度 截至 2025 年 11 月 26 日： 沪深 300 指数中，有 1 家公司处于预案阶段，0 家公司处于决案阶段，0 家 公司进入实施阶段，0 家公司已分红，20 家公司不分红； 中证 500 指数中，有 0 家公司处于预案阶段，0 家公司处于决案阶段，0 家 公司进入实施阶段，0 家公司已分红，47 家公司不分红； 中证 1000 指数中，有 0 家公司处于预案阶段，0 家公司处于决案阶段，0 家公司进入实施阶段，0 家公司已分红，142 家公司不分红。 行业成分股股息率比较 我们对当前已披露分红预案的个股股息率进行了统计，其中，煤炭、银行和 钢铁行业的股息率排名前三。 已实现及剩余股息率 截至 2025 年 11 月 26 日： 上证 50 指数已实现股息率为 2.52%，剩余股息率 0.35%； 沪深 300 指数已实现股息率为 2.03%，剩余股息率 0.20%； 上证 50 指数中，有 0 家公司处于预案阶段，0 家公司处于决案阶段，0 家 ...

证券研究报告 | 2025年11月27日 | 晨会纪要 | | --- | | 数据日期:2025-11-26 | 上证综指 | 深证成指沪深 | 300 指数 | 中小板综指 | 创业板综指 | 科创 50 | | --- | --- | --- | --- | --- | --- | --- | | 收盘指数（点） | 3864.18 | 12907.83 | 4517.62 | 13885.62 | 3748.87 | 1315.04 | | 涨跌幅度（%） | -0.15 | 1.02 | 0.60 | 0.27 | 0.73 | 0.98 | | 成交金额（亿元） | 7010.19 | 10823.26 | 4273.61 | 3572.96 | 5235.99 | 575.75 | 【常规内容】 行业与公司 机械行业周报:制造成长周报（第 35 期）-小鹏提出人形机器人百万台量 产规划，谷歌发布 Gemini 3 汽车行业专题:汽车智能化月报系列（三十）-9 月城区 NOA 渗透率达 16%， 小鹏发布第二代 VLA、Robotaxi、全新一代 IRON 传媒互联网周报：谷歌 Nano Bana ...

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3]. Core Views - The company reported a year-on-year revenue growth of 7.53% and a net profit growth of 39.03% for the first three quarters of 2025, with a revenue of 154.55 billion yuan and a net profit of 4.60 billion yuan [1]. - The LCD industry is experiencing a continuous optimization of its structure, with manufacturers adopting a demand-driven production strategy, leading to moderate fluctuations in TV panel prices [2]. - The company is expected to see a double-digit growth in OLED shipments for the year, driven by flagship models from leading brands and an increase in the penetration of foldable devices [2]. Financial Performance Summary - For Q3 2025, the company achieved a revenue of 53.27 billion yuan, representing a year-on-year increase of 5.81% and a quarter-on-quarter increase of 5.11% [1]. - The gross margin for Q3 2025 was reported at 14.44%, showing a year-on-year decrease of 3.0 percentage points but an increase of 1.4 percentage points quarter-on-quarter [1]. - The revenue forecast for 2025-2027 is projected to grow by 12.4%, 8.2%, and 9.3%, reaching 223.1 billion yuan, 241.3 billion yuan, and 263.8 billion yuan respectively [3][4]. Earnings Forecast and Financial Metrics - The net profit for 2025 is expected to be 6.53 billion yuan, with a year-on-year growth of 22.6% [4]. - The projected price-to-book (PB) ratios for 2025-2027 are 1.11, 1.07, and 1.01 respectively [3][4]. - The company’s earnings per share (EPS) is forecasted to be 0.17 yuan in 2025, with a growth rate of 22.6% [4].